Want to see ECOR full AI Analyst Report?
ECOR Stock Chart & Stats
$6.19
-$0.14(-2.26%)
At close: 4:00 PM EDT
$6.19
-$0.14(-2.26%)
Day’s Range― - ―
52-Week Range$4.16 - $10.50
Previous Close$6.05
Volume31.46K
Average Volume (3M)33.66K
Market Cap
$54.86M
Enterprise Value$54.64
Total Cash (Recent Filing)$10.04M
Total Debt (Recent Filing)$9.56M
Price to Earnings (P/E)―
Beta1.86
Next Earnings
Oct 29, 2026EPS Estimate
-0.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.70
Shares Outstanding9,015,885
10 Day Avg. Volume29,982
30 Day Avg. Volume33,656
Financial Highlights & Ratios
PEG Ratio-0.72
Price to Book (P/B)-22.29
Price to Sales (P/S)1.19
P/FCF Ratio-4.62
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$15.00Price Target Upside142.33% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.48
Revenue Forecast (FY)$41.92M
Bulls Say, Bears Say
Bulls Say
Top-line Revenue GrowthSustained multi-year revenue growth shows expanding commercial traction and increasing market adoption of gammaCore and related products. This scale supports operating leverage potential, improves coverage negotiation leverage with payors, and makes a path to fixed-cost absorption more achievable over months.
Very High Gross MarginsAn ~87% gross margin indicates strong product economics and pricing power for gammaCore therapies. High gross profitability creates structural room to cover SG&A and R&D, so with continued revenue scale the company has a durable lever to materially narrow operating losses and improve cash generation over the medium term.
Federal/VA Channel TractionStrong VA performance and low current penetration indicate a large, addressable federal channel with recurring purchase dynamics and reimbursement support. Expansion in VA/DoD and addition of experienced commercial leadership strengthen durable access to a concentrated, high-value buyer base and long-term revenue predictability.
Bears Say
Persistent Cash BurnOngoing negative operating and free cash flow reflect that core operations still consume material capital. Even with improved trends, continued cash burn creates near-term financing needs, increases dilution or debt risk, and pressures execution timelines for commercialization and R&D over the next several quarters.
Deteriorating Balance SheetNegative equity and rising debt reduce financial flexibility and increase the cost and complexity of raising capital. With modest total assets, further losses or working capital swings could constrain liquidity, limit strategic optionality, and raise refinancing or covenant risks in the medium term.
Commercial Concentration & VariabilityHeavy reliance on the VA/federal channel and limited current penetration create concentration risk: revenue growth depends on deeper adoption in a few channels. Separately, historically variable TACSTIM and other product revenues add execution uncertainty, making sustained, predictable top-line progression dependent on successful broader commercialization.
Electrocore News
ECOR FAQ
What was Electrocore Llc’s price range in the past 12 months?
Electrocore Llc lowest stock price was $4.16 and its highest was $10.49 in the past 12 months.
What is Electrocore Llc’s market cap?
Electrocore Llc’s market cap is $54.86M.
When is Electrocore Llc’s upcoming earnings report date?
Electrocore Llc’s upcoming earnings report date is Oct 29, 2026 which is in 81 days.
How were Electrocore Llc’s earnings last quarter?
Electrocore Llc released its earnings results on Aug 06, 2026. The company reported -$0.33 earnings per share for the quarter, beating the consensus estimate of -$0.422 by $0.092.
Is Electrocore Llc overvalued?
According to Wall Street analysts Electrocore Llc’s price is currently Undervalued.
Does Electrocore Llc pay dividends?
Electrocore Llc does not currently pay dividends.
What is Electrocore Llc’s EPS estimate?
Electrocore Llc’s EPS estimate is -0.26.
How many shares outstanding does Electrocore Llc have?
Electrocore Llc has 9,015,885 shares outstanding.
What happened to Electrocore Llc’s price movement after its last earnings report?
Electrocore Llc reported an EPS of -$0.33 in its last earnings report, beating expectations of -$0.422. Following the earnings report the stock price went up 20.746%.
Which hedge fund is a major shareholder of Electrocore Llc?
Currently, no hedge funds are holding shares in ECOR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Electrocore Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$15.00 (142.33% Upside)
$15.00 (142.33% Upside)
Blogger Sentiment
Bearish
ECOR Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth $563.7K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-61.72%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-3.48%
Trailing 12-Months
Company Description
Electrocore Llc
electroCore, Inc. is a commercial-phase medical device enterprise whose focus lies in developing and bringing to market a variety of non-invasive vagus nerve stimulation (nVNS) therapies. Currently, the firm is advancing gammaCore, a prescription-only nVNS therapy specifically engineered for adults to acutely treat the discomfort associated with both migraine and episodic cluster headaches. Its flagship offering, the gammaCore Sapphire, is a portable, rechargeable, and refillable device intended for either regular or intermittent use over many years. Established in 2005, its corporate headquarters are situated in Rockaway, New Jersey.
ECOR Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated a strong quarter of execution: record revenue, significant YoY growth, higher gross margins (87%), and meaningful improvement in adjusted EBITDA loss, all while reaffirming full-year guidance. Management also highlighted multiple catalysts (VA and DoD expansion, TruVega international launch, Quell OTC relaunch, R&D/clinical progress including PTSD work) and added experienced commercial leadership. Key risks discussed include a decrease in cash balances, Q1 seasonal cash burn and near-term capital timing, ongoing GAAP losses driven by nonrecurring charges, concentrated product penetration in the VA (only ~2.5%), and historically variable TACSTIM revenue. On balance, the positives around accelerating revenue, margin expansion, improving adjusted EBITDA, product and channel momentum, and clear operational priorities outweigh the near-term financial and execution risks presented on the call.View all ECOR earnings summariesECOR Stock 12 Month Forecast
Average Price Target
$15.00
▲(142.33% Upside)
Technical Analysis
Myomo
―
Modular Medical
―
NeuroOne Medical Technologies
―
Vivos Therapeutics
―
Adagio Medical Holdings
―
Ownership Overview
12.44% Insiders
2.89% Mutual Funds
0.05% Other Institutional Investors
82.10% Public Companies and
Individual Investors